|
| Home : BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH |
|
Dec 03
2018 |
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH |
|
BERGEN, Norway, Nov. 3, 2018 /PRNewswire/ -- 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) Phase II trial continues in combination with chemotherapeutics in first line AML Bemcentinib with decitabine cohort has... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/bergenbio-reports-43-response-rate-with-bemcentinib-monotherapy-in-axl-positive-r-r-aml-mds-patients-at-ash-855789043.html |
| |
|
Related News
|
» Anders Lönner, Chairman of the Board Karo Pharma AB, has Suddenly Passed Away
» Congress, White House on the brink of another government shutdown
|
|
|
